Drug Profile
Research programme: obesity therapy - AdipoGenix/Johnson And Johnson
Latest Information Update: 13 Apr 2012
Price :
$50
*
At a glance
- Originator AdipoGenix; Johnson & Johnson
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 16 Mar 2006 AdipoGenix achieved its third milestone in the collaboration with Johson And Johnson
- 20 Nov 2003 AdipoGenix has completed the initial screening of compounds selected by Johnson & Johnson
- 19 Dec 2002 Preclinical trials in Obesity in USA (unspecified route)